Welcome to our dedicated page for Eliem Therapeutics news (Ticker: ELYM), a resource for investors and traders seeking the latest updates and insights on Eliem Therapeutics stock.
Eliem Therapeutics, Inc. (ELYM) has communicated a multi-stage evolution that is reflected in its news flow, from early work in neuronal excitability disorders to a current focus on immune-mediated and autoimmune-driven inflammatory diseases. Company press releases describe how the acquisition of Tenet Medicines, Inc. and subsequent strategic decisions repositioned Eliem around its anti-CD19 monoclonal antibody program.
Recent news highlights include the closing of the Tenet Medicines acquisition, a concurrent private placement of common stock, and the decision to concentrate on budoprutug (also referred to as TNT119), an anti-CD19 antibody designed for a broad range of autoimmune diseases such as systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia and membranous nephropathy. Updates also cover the company’s addition to the Russell 2000 and Russell 3000 indexes, which the company notes as an important milestone in its public-market presence.
Earlier news items provide context on Eliem’s prior strategy in neuronal excitability, including preclinical data and development plans for its Kv7.2/3 program and ETX-123, as well as corporate reorganizations and the decision to halt that program while exploring strategic alternatives. Subsequent announcements detail leadership changes, the integration of Tenet’s team and the company’s intent to build its immunology pipeline.
Investors and observers following ELYM-related news can use this page to review historical press releases on strategic transactions, financing events, index inclusion, pipeline updates and the company’s announced rebranding to Climb Bio, Inc. Reviewing this sequence of news helps clarify how the business focus and lead assets have changed over time.
Eliem Therapeutics reported key business developments and financial results for Q2 2021. The company successfully completed its IPO, raising $92 million in gross proceeds, enhancing its cash runway through late 2023. With cash of $99.5 million as of June 30, 2021, Eliem is advancing two Phase 2a studies for ETX-810 targeting chronic pain, and preparing to initiate trials for ETX-155 in depressive disorders and epilepsy. R&D expenses surged to $5.8 million, contributing to a net loss of $8.7 million.
Eliem Therapeutics (NASDAQ: ELYM) has successfully closed its initial public offering (IPO) of 7,360,000 shares at $12.50 per share, raising $92.0 million in gross proceeds. This includes the full exercise of underwriters' options for 960,000 additional shares. The IPO positions Eliem to advance its development of therapies for neuronal excitability disorders affecting the peripheral and central nervous systems. The offering was managed by SVB Leerink, Evercore ISI, Stifel, and Guggenheim Securities.
Eliem Therapeutics announced the pricing of its initial public offering (IPO) of 6,400,000 shares at $12.50 each, aiming to raise approximately $80 million. The offering, which includes a 30-day option for underwriters to buy an additional 960,000 shares, is set to begin trading on the Nasdaq under the ticker symbol ELYM on August 10, 2021, with closure expected on August 12, 2021, subject to customary conditions. SVB Leerink, Evercore ISI, Stifel, and Guggenheim Securities are acting as joint bookrunners for the IPO.